VivoSeq
Cardiovascular

Ischaemic Stroke

1

Pipeline Programs↗

3

Active Trials↗

2

Companies Involved↗

Ischaemic Stroke is an early-stage landscape with 1 program across 2 companies. The most active players are EIP Pharma Inc, Eli Lilly.

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

E

EIP Pharma Inc

1 program

Phase 2Eli Lilly logo

Eli Lilly

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 21

Neflamapimod

EIP Pharma Inc

Phase 3
No programs
Approved
No programs

Analysis

Trial Status

4

clinical trials

Not yet recruiting1 · 25%
Active, not recruiting1 · 25%
Recruiting1 · 25%
Completed1 · 25%

Clinical Trials

Trial Activity

Application of Cognitive Care Bundle to Ischaemic Stroke Patients and Its Effect on Post-Stroke Cognitive Outcome: A Pilot Randomised Controlled Trial
Not yet recruiting·NNational University of Malaysia·Preclinical·NCT07610291·50 enrolled
A Double-Blind, Placebo-Controlled, Proof-of-Concept Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod on Recovery After Moderate to Severe Acute Ischaemic Stroke
Active, not recruiting·EEIP Pharma Inc·Phase 2·NCT06987643·90 enrolled
Efficacy and Safety of Minocycline in Patients With Acute Ischaemic Stroke Receiving Intravenous Thrombolysis (EMPHASIS-2): A Multicenter, Randomized, Double-blind, Placebo-parallel Controlled Trial
Recruiting·BBeijing Tiantan Hospital·Phase 3·NCT07526987·934 enrolled
Effect of Combined Anodal tDCS and Peripheral Nerve Stimulation on Motor Recovery in Acute Stroke
Completed·IInstitut National de la Santé Et de la Recherche Médicale, France·Preclinical·NCT01207336·20 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)